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Abstract
Background: LGD1069 (Targretin
®) is a selective retinoid X receptor (RXR) ligand, which is used in patients for
cutaneous T-cell lymphoma. Our published study reported that LGD1069 inhibited tumor-induced angiogenesis in
non-small cell lung cancer. In present study, we found that LGD1069 suppressed the proliferation, adhesion,
invasion and migration of endothelial cells directly, and affected the expression of vegf and some matrix genes.
Methods: Human umbilical vein endothelial cells (HUVECs) were used for in vitro study. MTT assay and
Sulforhodamine B assay were used for cell viability assay; the tube formation assay was used to investigate the
effect of LGD1069 on angiogenesis in vitro. In vitro adhesion, migration and invasion of HUVEC cells were analyzed
by Matrigel adhesion, migration and invasion assay. Gene expressions were measured by RT-PCR and Western blot
analysis.
Results: Our data showed here that LGD1069 inhibited the activation of TGF-b/Smad pathway significantly.
Furthermore, it was demonstrated that expression of Runx2 was suppressed pronouncedly during incubation with
LGD1069. Runx2 is a DNA-binding transcription factor which plays a master role in tumor-induced angiogenesis
and cancer cells metastasis by interaction with the TGF-b/Smad pathway of transcriptional modulators.
Conclusions: Our results suggested that LGD1069 may impair angiogenic and metastatic potential induced by
tumor cells through suppressing expression of Runx2 directly on human endothelial cells, which may point out
new pathway through which LGD1069 display anti-angiogenic properties, and provide new molecular evidence to
support LGD1069 as a potent anti-metastatic agent in cancer therapy.
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Background
Carcinomas are the most frequent type of human malig-
nancies, and the vast majority of cancer deaths are
caused by the formation of metastases rather than by
the primary tumor itself [1]. Despite its clinical impor-
tance, spreading to distant organs remains the most
insidious aspect of solid cancers, and the complexities
about the genetic and biochemical determinants remain
poorly understood. But for more than a century, cancer
biologists paid lots of attention to this aspect. Based on
current findings in this field, Gupta et al. posed a frame-
work of cancer metastasis. There are several key steps in
the biological cascade of metastasis: altered cellular
adhesion and cell motility, disruption of the basement
membrane and extracellular matrix, entry and survival
in circulation, exit into new tissues and eventual coloni-
zation of a distant site [2]. In addition, the development
of new vessels, or angiogenesis, contributes to the pro-
gressive growth and metastasis of solid tumors [3,4],
and has already become an important target of anti-can-
cer therapy [5].
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(RXR) ligand, termed rexinoid [6], which is used in
patients for cutaneous T-cell lymphoma [7]. Several
observations demonstrated that LGD1069 prevented and
overcome acquired drug resistance in advanced breast
cancer [8] and non-small cell lung cancer [9], and also in
advanced prostate cancer [10]. Besides the efficacy on
cancer therapy, LGD1069, as well as other retinoids such
as all-trans retinoic acid, 9-cis retinoic acid and CD2409
etc., are frequently used for the treatment of skin disor-
ders such as psoriasis, delayed-type skin hypersensitivity
reactions, bullous diseases, and Kaposi’s sarcoma, which
are characterized by abnormal neovascularization [11].
Led by these clinical properties of LGD1069, we tested
whether this rexinoid would cause similar effects on
tumor neovascularization to those skin disorders pre-
viously. It was shown that LGD1069 inhibited tumor
induced-angiogenesis through decreasing VEGF secre-
tion via suppressing phosphorylation of JNK and ERK in
non-small cell lung cancer [12]. So, we wondered
whether there are direct impacts of LGD1069 on human
endothelial cells. In the current study, it was reported
that LGD1069 inhibited the proliferation, invasion and
migration of endothelial cells directly, and affected the
expression of vegf and matrix-related genes. Further-
m o r e ,w es h o w e dh e r et h a tL G D 1 0 6 9d e c r e a s e dt h e
expression of Runx2, a master transcriptional factor
which regulates angiogenesis and metastasis through
specific DNA-binding motif, and the activity of TGF-b/
Smad pathway significantly.
Methods
Materials
The RXR-selective retinoid used in this study, LGD1069,
(Targretin
®), was purchased from Sigma Chemicals (St
Louis, MO). A stock solution (1 mM) was prepared by
dissolving LGD1069 in DMSO and stored at 4°C for
<1 month before use. The vehicle (DMSO) was used as
a control in all experiments at a final concentration of
0.1%.
Cell culture
HUVECs (Human umbilical vein endothelial cells) were
isolated as previously described by Jaffe et al [13], from
umbilical cords obtained from a parturient at Beijing
Obstetric Hospital who gave written informed consent.
The study protocol was approved by the IRB (Institu-
tional Review Board) of Beijing Obstetric Hospital.
HUVECs were routinely grown in M199 (Gibco, Grand
Island, NY) supplemented with 10% fetal bovine serum
(FBS) (Gibco) and endothelial cell growth supplement
(ECGS) (BD Biosciences, Bedford, MA) at 37°C and 5%
CO2. HUVEC between P3 and P4 were used for all
experiments.
MTT assay
Cell viability was assayed using a MTT assay. Briefly, log
phase cells were plated in 96-well plates at a density of
3×1 0
4 cells per well in the presence of 2 ng/ml VEGF
(physiological concentration) in 10% FBS media by for
24 h incubation, and then sufficient volumes of stock
solution of LGD1069 and DMSO were added to the cul-
ture medium, in order to obtain different treatment
doses. Then the vehicle and a range of LGD1069 were
co-incubated with cells for different time. Three dupli-
cate wells were set up in each sample. At least three
independent experiments were carried out. After treat-
ment, cells were incubated with 3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT, Sigma
Chemical Company) (final concentration 0.5 mg/ml) for
4 h at 37°C. The media was carefully removed from
each well and 200 μl of DMSO was added. The plates
were gently agitated until the color reaction was uni-
form and the OD570nm and OD450nm were deter-
mined using a microplate reader (WellScan MK3,
Labsystems Dragon). The data were analyzed using a
SlideWrite program to determine the IC50 value of
LGD1069. Media only treated cells served as the indica-
tor of 100% cell viability.
Sulforhodamine B assay
The growth inhibition effect of LGD1069 on endothelial
cells was also examined with the sulforhodamine B
(SRB) assay. Briefly, HUVEC cells were seeded in 96-
well plates (2,000 cells per well) and co-incubated with
2 ng/ml VEGF overnight. Then, triplicate wells were
treated with various concentrations of LGD1069. Three
duplicate wells were set up in each sample. At least
three independent experiments were carried out. After
96 h, the culture medium was discarded, 10% (w/v) pre-
cooled (4°C) trichloroacetic acid (100 μl) was added to
each well, and the cells were fixed at 4°C in a refrigera-
tor for 1 h. Each well was then stained with 100 μl0 . 4 %
SRB (w/v) in 1% acetic acid (v/v) for 15 min. The plates
were washed with 1% acetic acid (v/v) for removal of
unbound dye, air dried, and then treated with 150 μl
per well 10 mM Tris base (pH 10.5) to dissolve the
bound dye. The absorbance in each well was read with a
microplate reader (WellScan MK3, Labsystems Dragon)
at 515 nm. The data were analyzed using a SlideWrite
program to determine the IC50 value of LGD1069.
Media only treated cells served as the indicator of 100%
cell viability.
Tube Formation Assay
The tube formation assay was used to investigate the
effect of LGD1069 on angiogenesis in vitro. The meth-
ods were described previously [5]. In briefly, a 96-well
plate was coated with 80 μl liquid Matrigel per well,
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HUVEC cells were seeded at a density of 3 × 10
4 cells
per well in 100 μl complete culture medium containing
different concentrations of LGD1069 or vehicle (con-
trol), then 100 μl serum-free M199 medium contained
VEGF (final concentration is 2 ng/ml) was added. Plates
w e r ei n c u b a t e df o r2 4ha t3 7 ° Ca n d5 %C O 2 (sufficient
for formation of an intact network in the control
group). Images were recorded by an inverted micro-
scope (Olympus, IX70, Japan), and total vessel lengths
were counted with ImagePro plus 5.0 image analysis
software (Media Cybernetics, Inc, Silver Spring, MD).
In vitro assays of HUVECs adhesion
96-well microtiter plates were pre-coated with 10 μl
Matrigel (0.5 μg/ml) and incubated at 4°C overnight.
Wells were blocked with 20 μl M199 containing 2%
BSA for 1h at 37°C. The exponential phase HUVE cells
were harvested, and re-suspended in serum-free M199
medium supplemented with 0.1% BSA. The cells (5 ×
10
4/well) were seeded in wells and co-incubated with 2
ng/ml VEGF at 37°C in a 0.5% CO2 atmosphere for 2h
with or without LGD1069. The wells were washed thrice
with PBS to remove unattached cells, then the attached
cells were incubated with MTT and the absorbance was
measured at 570 and 450 nm. Each assay was performed
in triplicate. Three independent experiments were
repeated [14].
Matrigel Invasion Assay
In vitro invasion of HUVEC cells was measured by the
invasion of cells through 48-well microchemotaxis plates
(AP 48, Neuro Probe, Gaithersburg, MD) with wells
separated by a Polyvinylpyrrolidone-free polycarbonate
filter with an 8 μm pore size [15]. Briefly, the polycarbo-
nate membrane was pre-coated with 5 μg of fibronectin
in a volume of 50 μl on the rough (lower) surface. The
Matrigel was diluted to 100 μg/ml with cold PBS and
applied to the smooth (upper) surface of the filters (5
μg/filter), and dried at room temperature. The lower
compartments of the plates were filled with 30 μl M199
containing 0.1% BSA. Log-phase cells were harvested
and washed thrice with serum-free M199, and re-sus-
pended to a final concentration of 2 × 10
6/ml in M199
with 0.1% BSA. Cell suspensions (100 μl) with or with-
out LGD1069 were added to the upper compartment
and with 2 ng/ml VEGF(final concentration) for 24 h at
37°C in a 5% CO2 atmosphere. The filters were fixed
with methanol and stained with Haematoxylin for 10
min, washing with distilled water, and then stained with
Eosin Y for 30s. The cells on the upper surface of the
filters were removed by wiping with cotton swabs. The
cells invading the lower surface of the filter through
Matrigel and filter were manually counted under a
microscope at a magnification of × 200, and each assay
was performed in triplicate.
Matrigel Migration Assay
In vitro migration of HUVECs was measured by AP 48
chamber (Neuro Probe, Gaithersburg, MD), similar to in
vitro invasion assay. Briefly, the underside of polycarbo-
nate membrane was coated with 20 μg/ml fibronectin
o v e r n i g h ta t4 ° C .3 0μl of M199 (with 10% FBS and 10
μg/ml Collagen I) was added to the lower chamber, and
the chamber was covered by filter. HUVECs were trypsi-
nized and washed by FBS-free M199, then 100 μl of cell
suspensions (in FBS-free M199, containing 2 × 10
5 cells)
with or without LGD1069 were added to the upper
chambers and co-incubated with 2 ng/ml VEGF over-
night at 37°C. Determination of migrated cells is the
same as what was described in Matrigel Migration
Assay.
RT-PCR assay
Untreated and treated cells with LGD1069 were washed
twice with cold PBS. Total RNA was isolated by Trizol
reagent according to the manufacturer’sp r o t o c o l( I n v i -
trogen, Carlsbad, CA). RNA was dissolved in diethylpyr-
ocarbonate (DEPC)-treated water (0.1% DEPC was
added to water overnight and then autoclaved 20 min to
destroy DEPC). According to the manufacturer’s
instructions (TaKaRa, Dalian, China), reverse transcrip-
tion was performed at 42°C in the presence of 5 units of
AMV reverse transcriptase and 1 μg of RNA for 60 min-
utes. AMV RT inactivation and RNA/cDNA/primer
denaturation were performed at 95°C for 5 minutes.
cDNA was stored at -20°C. The PCR profile was as fol-
lows, 10 min at 95°C, followed by several cycles of 30s
at 95°C and 1 min at 60°C. The PCR product was sepa-
rated by 2% agarose gel electrophoresis, and the gels
were viewed by UV transillumination, photographed by
Kodak 120 gel imaging system. Primers, Tm, and cycles
were listed on Table 1.
MMPs activities assay
MMPs activities were measured by SensoLyte
® 520
MMPs Assay Kit according to the manufacturer’s proto-
col (AnaSpec, Fremont, CA). Briefly, Untreated and
treated cells with LGD1069 were collected and homoge-
nized by assay buffer containing 0.1% Triton-X 100, and
centrifuged for 15 min at 10000X g at 4°C. Collect the
supernatants and store at -70°C until use. To activate
MMPs before the measurement, the supernatants were
incubated with 4-aminophenylmercuric acetate (APMA)
for 1 h at 37°C. Then, 50 μl MMPs-containing samples
were added to 96-well plate per well. Add 50 μl per well
of MMPs substrate solution to the sample and control
wells. Mix the reagents by shaking the plate gently for
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stop solution was added per well, and mix the reagents
and measure fluorescence intensity at Ex/Em = 490/520
nm(Victor3, Perkin Elmer, Waltham, MA).
Western blot analysis
HUVECs were washed once with PBS and then lysed by
the addition of 1 ml lysis buffer (10 mmol/l Tris, pH 7.6,
150 mmol/l NaCl, 5 mmol/l EDTA, pH 8.0, 10 ml/l Triton
X-100, 1 mmol/l DTT) containing 0.1 mmol/l PMSF.
After 30 min on ice, lysates were collected and clarified by
centrifugation at 15,000 g for 10 min at 4°C. Aliquots of
whole cell lysates were subjected to 10% SDS-PAGE and
then transferred to Hybond nitro blotting membranes.
The membranes were blocked with 3% bovine serum albu-
min in Tris-buffered saline containing 0.5 ml/l Tween-20
( T T B S )a n dt h e np r o b e dw i t he i t h e ra n t i - S m a d 2 / 3 ( s c -
6032), p-Smad2/3(sc-11769), Runx2(sc-8566), and anti-b-
actin (sc-1616) antibodies in 30 g/l bovine serum albumin
in TTBS. Positive antibody reactions were visualized using
UVP EC3-410 luminescence system.
Statistical analysis
The mean values were obtained from at least three inde-
pendent tests. The data are presented as mean ± S.D.,
and analyzed with the SPSS software program (version
10.0 for Windows; SPSS INC., Chicago, IL). Comparison
among different groups was carried out by analysis of
variance (the one-way ANOVA). Differences between
means were considered statistically significant at p < 0.05.
Results
Inhibition of proliferation on endothelial cells
To examine whether LGD1069 was capable of inhibition
the proliferation of HUVEC, we performed MTT assay
with a range of LGD1069 and different time. HUVECs
were treated with 0.8, 4, 20 and 100 μM LGD1069 for
24h, 48h and 96h, respectively. The inhibition of
LGD1069 on HUVECs was given in Figure 1A. Data
showed that treatment of LGD1069 for 96h resulted in
a dose-dependent inhibition of cells proliferation with
the IC50 value of 16.6 ± 6.7 μM when the cells were co-
incubated with VEGF at 2 ng/ml. A slight inhibition was
observed on the cells incubated with LGD1069 for 48h.
But on the cells treated for 24h, there were no inhibition
of proliferation. In addition, we also tested the effects of
LGD1069 on HUVECs viability by SRB assay. It’ss h o w n
that treatment with LGD1069 for 96h resulted in growth
inhibition, similar to the results of MTT assay. The IC50
value was 21.4 ± 5.9 μM (Figure 1B).
From these results, we concluded that alteration of
HUVECs viability depended on the final concentration
and incubated time of LGD1069. Therefore, the investi-
gations of antiangiogenic effects on HUVECs would be
carried out at proper concentrations and exposure time,
which did not cause significant proliferative inhibition.
LGD1069 directly decreased HUVECs tube formation
Capillary formation starts with endothelial cell differen-
tiation and tube formation in vitro is a consequence of
endothelial cell differentiation. We tested whether
LGD1069 decreased the formation of tubes by HUVECs
on Matrigel induced by VEGF in vitro. Control HUVECs
formed a mesh of tubes within 24 h (Figure 2 and Table
2), whereas those treated with LGD1069 did not.
HUVECs treated with low concentrations (7.5 and 15
μM) of LGD1069 differentiated into short tubes but
were unable to form meshes, whereas those treated with
higher concentrations (30 μM) remained dotted on the
Matrigel without obvious morphological changes. As
shown in Figure 1a, treatment of HUVECs with 100 μM
for 24h showed 2.27% inhibition of cell growth rate,
indicating that the observed ability of LGD1069 to inhi-
bit tube formation was not due to cell growth inhibition.
LGD1069 inhibited HUVECs invasion through
reconsititutive basement membrane
As endothelial cells invasion is critical for the processes
of angiogenesis and metastasis, we studied the effect of
LGD1069 on HUVECs invasion in vitro.I nt h i ss t u d y ,
we used fibronectin as a chemo-attractant on the lower
surface of polycarbonate membrane. Here, we found
that HUVECs invasion was dose-dependently blocked by
LGD1069 (Figure 3), with inhibition of 1.31, 26.40 and
66.88% at concentrations of 7.5, 15 and 30 μM
LGD1069 in normal culture conditions, respectively.
LGD1069 suppressed HUVECs migration
With similar methods to invasion assay, effects of
LGD1069 on HUVEC migration in vitro were tested. In
this study, we used fibronectin as a chemo-attractant on
Table 1 PCR Primers
Primers Product length
(bp)
Tm (°C)
MMP-
2
S:5’-
GTGCTGAAGGACACACTAAAGAAGA
580 53
A:5’-
TTGCCATCCTTCTCAAAGTTGTAGG
MMP-
9
S:5’-CGGCACGGCAATGCTGAT 507 55
A: 5’-AGGGCGAGGACCATAGAGG
VEGF S:5’-TCCAGGAGTACCCTGATGAG 204 49
A:5’-ATTCACATTTGTGTGCTGT
b-
actin
S:5’-GTGGGGCGCCCCAGGCACCA 540 55
A:5’-
CTTCCTTAATGTCAVGCACGATTTC
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matrigel was used. Here, we found that migration of
HUVECs was dose-dependently blocked by LGD1069
(Figure 4a), with inhibition of 3.80, 46.13 and 73.75% at
concentrations of 7.5, 15 and 30 μM LGD1069 in nor-
mal culture conditions, respectively.
LGD1069 decreased HUVEC adhesion in vitro
Since adhesion of endothelial cells to the basement
membranes is an important step of angiogenesis and
metastasis, we also examined the effects of LGD1069 on
HUVECs adhesion in vitro when the cells were co-incu-
bated with VEGF at 2 ng/ml. As shown in Figure 4b,
the adhesion rate to Matrigel was 86.49, 55.73 and
38.01% when HUVECs were incubated with 7.5, 15 and
30 μM LGD1069 for 2 hours. It’s revealed that
LGD1069 could inhibit endothelial cell adhesion to the
component of basement membrane in a concentration-
dependent fashion.
LGD1069 suppressed MMPs activation
To determine whether LGD1069 influenced the activ-
ities of endothelial cells-secreted- metalloproteinases to
inhibit invasion and angiogenesis, we measured the
MMPs activities in HUVECs by FRET-based assay. It’s
revealed that LGD1069 suppressed FRET substrate
cleavage significantly in a does-dependent manner
(Figure 5).
Figure 1 Anti-proliferative properties of LGD1069 in endothelial cells. Panel A showed the results analyzed by MTT assay. Cells were
incubated with LGD1069 in the presence of 2 ng/ml VEGF, at different concentrations for 24, 48 and 96h, respectively. The IC50 value for 96h
was 16.6 ± 6.7 μM. Panel B is the results of SRB assay. The HUVEC cells were treated with LGD1069 for 96h at different concentrations, and the
IC50 value was 21.4 ± 5.9 μM. Vehicle (DMSO) was used as a control in both of the viability assay. Data were expressed as mean ± SD. (n = 3).
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Then, expression of matrix metalloproteinases (mmps) in
HUVECs were examined by RT-PCR assay, in order to
find out whether LGD1069 down-expressed endothelial
cell-secreted metalloproteinases to decrease its activities.
It’s revealed that LGD1069 decreased the expression of
mmp-2 and mmp-9 at RNA level (Figure 6a and 6b).
LGD1069 down-regulated activation of Smad2/3 and
expression of Runx2
We also tested the effects of LGD1069 on expression
level of Runx2 in HUVECs when VEGF at pathologic
level was present. Western Blotting assay demonstrated
that LGD1069 decreased the expression of Runx2 at
protein levels (Figure 7a and 7b). It’sr e v e a l e dt h a t
LGD1069 significantly suppressed Runx2 expression in a
dose-dependent fashion. Since Runx2 is a DNA-binding
transcription factor that interacts with the TGFb/Smad
family of transcriptional modulators to stimulate cell
proliferation and tumor progression, we looked for the
signs of LGD1069 affecting the phosphorylation of
Smads in HUVECs simulated by VEGF. Western blot-
ting showed that LGD1069 treatment down-regulated
the phosphorylation of Smad2/3 significantly, but there
are no changes of the expression of total Smad2/3.
Discussion
LGD1069, a selective retinoid X receptor agonist, is used
in patients for cutaneous T-cell lymphoma [7], and is also
demonstrated that it is an efficacious chemopreventive
and chemotherapeutic agent in a number of preclinical
rodent models breast cancer [7,16-18]. Furthermore,
LGD1069 was shown recently to prevent tumor-induced
angiogenesis and metastasis. Yen and his colleagues deter-
mined the influence of this retinoid X receptor agonist on
angiogenesis and metastasis in solid tumors [19]. More-
o v e r ,i np r e v i o u ss t u d y ,w ea l s od e m o n s t r a t e dt h a t
LGD1069 decreased tumor-induced angiogenesis. In that
study we found LGD1069 impair the capacity of vessel
Figure 2 Effects of LGD1069 on tube formation of HUVECs induced by VEGF. HUVECs were seeded in Matrigel-coated 96-well plates, and
untreated or treated with LGD1069, in the presence of 2 ng/ml VEGF. Vehicle (DMSO) was utilized as a control. A. Control; B. LGD1069 7.5 μM;
C. LGD1069 15 μM; D. LGD1069 30 μM (100X).
Table 2 Microvessel Formation of endothelial Cells in
vitro (24h)
Group Total Vessel Actual Perimeter Length
(APLT) ± SD(μm)
Formation
Rate (%)
CTRL 835.2 ± 91.1 100.00%
LGD1069
(7.5 μM)
761.9 ± 59.7 91.22%
LGD1069(15
μM)
601.8 ± 37.4
a 72.05%
LGD1069(30
μM)
109.2 ± 10.6
b 13.07%
HUVECs were seeded in Matrigel-coated 96-well plates, and untreated or
treated with LGD1069, in the presence of 2 ng/ml VEGF. Vehicle (DMSO) was
utilized as a control. Five fields were counted for each well, and each
concentration repeated three wells. Data were expressed as mean ± SD. a p <
0.05, b p < 0.01 compared with control (n = 3).
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secretion in human non-small cell cancers. Thus, we
sought to determine whether LGD1069 exerts its anti-
angiogenic ability by directly impairing activation of
human endothelial cells and to identify the underlying
story here. In the current study, we found that LGD1069
inhibited proliferation and survival of endothelial cells,
and destroyed vessel-network formation on Matrigel. In
addition, in vitro analysis indicated that LGD1069 attenu-
ated endothelial cell adhesion, migration and inhibited cell
invasion through reconstituted extracellular matrix (ECM).
Angiogenesis denotes the formation of new blood ves-
sels from pre-existing vessels. Angiogenetic factors, such
as fibroblast growth factors (FGFs) and vascular
endothelial growth factors (VEGFs), regulate endothelial
cells to secrete several proteases (such as MMPs and
TIMPs) and plasminogen activators (such as uPA),
resulting in the degradation of the vessel basement
membrane, and the formation of stable new vessels
[20-22]. Besides activating endothelial cells, VEGFs
binding to their specific receptors expressed on cell sur-
face, also regulate proliferation and survival of endothe-
lial cells, and microvascular permeability [19; 23]. Led
by these findings and our published study, we tested
whether there are effects on biological behaviors of
ECM related enzymes. Our data showed that at the pre-
sence of VEGF (2 ng/ml), LGD1069 inhibited expression
of MMP-2, MMP-9 in endothelial cells. Collectively,
these results indicated that the anti-angiogenetic and
anti-metastatic properties of LGD1069 may be due to
the inhibition of expression of matrix-related proteases
in endothelial cells, resulting in inhibiting endothelial
cell adhesion, migration, invasion and proliferation.
These data suggest that LGD1069 may impede the acti-
vation of endothelial cells directly, and its effects on
angiogenesis and metastasis may occur through activa-
tion of protease expression and events that regulate
angiogenesis.
Runx2 is a member of the runt family of DNA-bind-
ing transcription factor which possesses a highly
Figure 3 LGD1069 inhibited the invasion of HUVECs in AP48 chamber. HUVECs were seeded in upper compartments of AP48 chamber,
and untreated or treated with LGD1069, in the presence of 2 ng/ml VEGF. Cells on the lower face of the membrane were counted by the
method described under materials and methods. Vehicle (DMSO) was utilized as a control. Five fields were counted for each chamber, and each
concentration repeated three chambers (100X). A. Control; B. LGD1069 7.5 μM; C. LGD1069 15 μM; D. LGD1069 30 μM; E. statistical results. b p <
0.01 compared with control (n = 3).
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domain. It plays essential roles for the formation of ske-
leton[24]. Qiao et al. reported that Runx2 DNA-binding
activity is elevated in proliferating endothelial cells [25].
Recent Studies showed that Runx2 mediates endothelial
cell migration and invasion during tumor angiogenesis
[26]. Furthermore, it was found that Runx2 is ectopically
expressed in metastatic cancer cells but not in non-
metastatic cancer cells, and that several genes required
for bone development and turnover, such as opn, bsp,
mmp12 etc., are activated by Runx2 [27]. It’ well known
that this cohort regulated by Runx2 is essential media-
tors of tumor invasion and metastasis. Pratap et al.a l s o
demonstrated that Runx2 activates the “vicious cycle” of
TGF- b-mediated tumor growth and metastatic bone
disease [26]. Therefore, Harada and Rodan et al.p r e -
s u m e dt h a tR u n x 2i sa“master” transcription factor in
the development of metastatic foci in several solid
tumor [28]. Given the important role of Runx2 in can-
cer-induced angiogenesis and metastasis, we wondered
whether it plays a role in the inhibition of MMP-2 and
MMP-9 expression induced by LGD1069. The following
specific studies will test this hypothesis. Data from cur-
rent study suggested that LGD1069 inhibited expression
of Runx2 and phosphorylation of Smad2/3, but no
effects were found on expression of total Smad2/3.
In conclusion, we demonstrated here that LGD1069 may
impairs metastatic potential in solid tumor, and the inhibi-
tory effects of LGD1069 were due to its ability to inhibit
endothelial cell growth and interfere with adhesion, migra-
tion and invasion of endothelial cells directly. These effects
of LGD1069 on endothelial cells may be associated with
inhibition of activation of Runx2 protein by interacting
with the TGF-b/Smad family. These findings have impor-
tant implications for patients with malignant diseases. For
example, LGD1069 can be used alone or incorporated
with other conventional modalities such as radiation and
chemotherapy to improve the efficacy of these treatments
as well as to prevent development of distant metastasis.
However, there are several questions arising from our
data. Such as, whether is there a direct interaction
between Runx2 and RXRs, which both are DNA-binding
transcription factors? Whether are the effects on cell
behaviors and expression of molecules of LGD1069
Figure 4 LGD1069 inhibited the migration and adhesion of
HUVECs. For migration assay, HUVECs were seeded in upper
compartments of AP48 chamber, and untreated or treated with
LGD1069, in the presence of 2 ng/ml VEGF. Cells on the lower face
of the membrane were counted by the method described under
materials and methods. Vehicle (DMSO) was utilized as a control. b
p < 0.01 compared with control (n = 3). For adhesion assay,
HUVECs were seeded in Matrigel-coated 96-well plates, and
untreated or treated with LGD1069, in the presence of 2 ng/ml
VEGF. The number of adhesive cells was evaluated by MTT assay.
Vehicle (DMSO) was utilized as a control. Values were normalized to
the mean number of adhesive control cells and presented as mean
± SD percentage of adhesion (n = 3). b p < 0.01 compared with
control. Panel A is results from migration assay, and panel B shows
the results of adhesion assay.
Figure 5 Effects of LGD1069 on metalloproteinases activities in
HUVECs. HUVECs were incubated for 12 h in medium containing
vehicle (DMSO, Line 1) or 7.5 μM, 15 μM, and 30 μM LGD1069, in
the presence of 2 ng/ml VEGF. Data were expressed as mean ± S.D.
a p < 0.05, b p < 0.01 compared with control.
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Page 8 of 11Figure 6 Effects of LGD1069 on metalloproteinases and vegf mRNA expression in HUVECs by RT-PCR assay. HUVECs were incubated for
12 h in medium containing vehicle(DMSO, Line 1) or 7.5 μM (Line 2), 15 μM (Line 3), and 30 μM (Line 4) LGD1069, in the presence of 2 ng/ml
VEGF. The expression of a housekeeping gene b-actin was used to normalize gene expression level. Error bars represent the standard deviation
of three replicate experiments. Panel A: RT-PCR analysis of metalloproteinases and vegf genes expression. Line M was DNA marker. Pane B:
densitometric analysis of electrophoretic bands. Intensities were normalized to a b-actin signal. Data were expressed as mean ± S.D. a p < 0.05,
b p < 0.01 compared with control.
Figure 7 Suppression of p-Smad2/3 phosphorylation and Runx2 expression in human endothelial cells after incubation with LGD1069
for 24 h, in the presence of 2 ng/ml VEGF. (A) Western blot analysis of protein lysates. (B) densitometric analysis of electrophoretic bands.
Intensities were normalized to a b-actin signal. Line 1: Control; Line 2: LGD1069 7.5 μM; Line 3: LGD1069 15 μM; Line 4: LGD1069 30 μM. Vehicle
(DMSO) was utilized as a control. Data were expressed as mean ± SD; b p < 0.01 compared with control (n = 3).
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Page 9 of 11coincidental or directly causes and effects? Recently, the
work from Hoover et al. [ 2 9 ]m a yp r o v i d eal i t t l eb i t
clues, but not all. They reported that retinoids, such as
LGD1069 and 9-cis RA, directly regulated Smad activa-
tion and sub-cellular accumulation via RXR-a[29]. From
these data, it seems that there exist indirect association
between RXRs and Runx2. Therefore, it is worthwhile to
further explore the role and regulation in of Runx2 in
endothelial cells, and to figure out the cross-talk between
Retinoic receptors and Runx2 activity. On-going research
is directed towards understanding the underlying story of
effects of LGD1069 on Runx2 in endothelial cells and
tumor cells. Information obtained from these studies will
have significant impact on the therapeutic use of
LGD1069 in treatment of those malignant diseases.
Conclusions
Our results suggested that LGD1069 may impair angio-
genic and metastatic potential induced by tumor cells
through suppressing expression of Runx2 directly on
human endothelial cells, which may point out new path-
way through which LGD1069 display anti-angiogenic
properties, and provide new molecular evidence to sup-
port LGD1069 as a potent anti-metastatic agent in can-
cer therapy.
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